Document Type : Case Report


1 Assistant Professor, Faculty of Medicine, Clinical Research Development Center of children’s Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

2 Assistant Professor of Pediatric Infectious Disease, Department of Pediatrics, School of Medicine Hormozgan University of Medical Sciences, Bandar Abbas, Iran

3 3. Assistant Professor of Assistant Professor of Pediatric Cardiology, Department of Pediatrics, School of Medicine Pediatrics hospital ,Hormozgan University of Medical Science, Bandar Abbas, Iran

4 Department of neonatology, NIMS Medical College, SobhaNgar, Jaipur, Rajasthan, India

5 Assistant Professor, Department of Pediatric Pulmonology, Mofid Pediatrics Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran



INTRODUCTION: The accurate incidence of different cardiovascular consequences of COVID-19 in the pediatric population has been inadequately defined due to ongoing genotype changes in the virus. Although COVID-19 is known to increase inflammatory markers associated with atrial arrhythmias, the contemporary literature has poorly described new onset arrhythmias as a complication in previously healthy neonates with COVID-19.
CASE PRESENTATION: A twenty-day-old female term neonate, born by caesarean section with immediate cry, developed labored breathing, cyanosis, and tachycardia after having close contact with a confirmed case of COVID-19. The neonate developed atrial flutter, which was refractory to cardioversion and drugs, namely Amiodarone, Flecainide, and Propranolol. The authors treated the neonate with IVIG. This is the first reported case of atrial flutter in the neonatal period secondary to COVID-19.
CONCLUSION: Since the start of the SARS-CoV-2 pandemic, all attention and concerns have been mainly on respiratory manifestations and complications. The cardiovascular complications and treatment have been neglected. This case reports tachyarrhythmia (Atrial Flutter) as an unusual presentation of acute COVID-19 in the neonatal population and shows the role of IVIG in the treatment of refractory arrhythmias.


1. Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M, et al., Heart Disease and Stroke Statistics-2016 Update: A Report From the American ‎Heart Association. Circulation 2016; 133: e38-e360.
2. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes 2019; 12: e005375.
3. Vogel B, Claessen B, Arnold S, Chan D, Cohen D, Giannitsis E, et al., ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019; 5: 39.
4. Stebbins A, Mehta R, Armstrong P, Lee K, Hamm C, Van de Werf F, J et al., A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2010; 3: 414-422.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.‎
6. Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 2011; 31: 433-440.
7. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic ‎review and meta‐analysis. ESC Heart Fail 2017; 4: 40-45.
8. Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010; 145: 257-258.
9. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al., Effect of Allopurinol Pretreatment on Free Radical Generation after Primary Coronary Angioplasty for Acute Myocardial Infarction. J Cardiovasc Pharmacol 2003; 41: 699-705.
10. Alemzadeh-Ansari MJ, Hosseini SK, Talasaz AH, Mohammadi M, Tokaldani ML, Jalali A, Pourhosseini H. Effect of High-Dose Allopurinol Pretreatment on Cardiac Biomarkers of Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial. Am J Ther 2017; 24: e723-e729.
11. Thygesen K, Alpert J, Jaffe A, Simoons M, Chaitman B, White H. For the Universal Definition of MI W. Third Universal Definition of Myocardial Infarction. Glob Heart 2012; 7: 275.
12. The TIMI Research Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-936.
13. Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J 2016; 68: 539-551.
14. Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, et al., Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. Hellenic J Cardiol 2017; 58(5): 360-365.
15. Ekeløf S, Jensen SE, Rosenberg J, Gögenur I. Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: A systematic review. Cardiovasc Drugs Ther 2014; 28: 173-181.
16. Ngu JMC, Ruel M, Sun LY. Left ventricular function recovery after revascularization: comparative effects of percutaneous coronary intervention and coronary artery bypass grafting. Curr Opin Cardiol 2018; 33(6): 633-637.